$32.4 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 8 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PMVP | PMV PHARMACEUTICALS INC | $19,217,000 | -16.5% | 1,614,911 | 0.0% | 59.24% | +38.5% | |
EIGR | EIGER BIOPHARMACEUTICALS INC | $4,224,000 | +19.5% | 560,990 | 0.0% | 13.02% | +98.2% | |
SERA PROGNOSTICS | $3,866,000 | -2.4% | 2,416,241 | 0.0% | 11.92% | +61.7% | ||
REAL | THE REALREAL | $3,531,000 | -39.8% | 2,354,080 | 0.0% | 10.88% | -0.1% | |
GKOS | Sell | GLAUKOS CORP | $870,000 | -94.5% | 16,347 | -95.3% | 2.68% | -91.0% |
AGTC | APPLIED GENETIC TECHNOL CORP | $381,000 | -64.8% | 1,404,515 | 0.0% | 1.17% | -41.6% | |
VERO | VENUS CONCEPT INC | $290,000 | -4.9% | 658,657 | 0.0% | 0.89% | +57.7% | |
DARE | DARE BIOSCIENCE INC | $62,000 | -18.4% | 62,065 | 0.0% | 0.19% | +35.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-10-25
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
GLAUKOS CORP | 28 | Q3 2023 | 33.0% |
EIGER BIOPHARMACEUTICALS INC | 24 | Q3 2022 | 17.7% |
APPLIED GENETIC TECHNOL CORP | 24 | Q3 2022 | 6.7% |
XENON PHARMACEUTICALS INC | 20 | Q3 2021 | 0.6% |
CIDARA THERAPEUTICS INC | 19 | Q2 2021 | 4.5% |
THE REALREAL | 18 | Q3 2023 | 62.6% |
KALVISTA PHARMACEUTICALS INC | 17 | Q4 2020 | 10.8% |
DARE BIOSCIENCE INC | 16 | Q3 2023 | 0.3% |
MACROGENICS INC | 14 | Q1 2020 | 19.2% |
PMV PHARMACEUTICALS INC | 13 | Q3 2023 | 67.5% |
View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.
Latest filings
Type | Filed |
---|---|
144 | 2024-02-27 |
13F-HR | 2023-10-20 |
13F-HR | 2023-07-21 |
13F-HR | 2023-04-27 |
13F-HR | 2023-01-31 |
13F-HR | 2022-10-25 |
13F-HR | 2022-08-02 |
13F-HR | 2022-04-13 |
13F-HR | 2022-01-25 |
13F-HR | 2021-10-19 |
View INTERWEST VENTURE MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.